A mechanistic study of rituximab and belimumab combination therapy in PR3 ANCA-associated vasculitis
Lead Research Organisation:
University of Cambridge
Department Name: Medicine
Abstract
There is a need for new therapies to reduce time to remission in patients suffering from ANCA associated Vasculitis treated with Rituximab. This project mechanistically investigates the utility of targeting the Bcell survival factor B-Lys in combination with rituximab in reducing remission in the setting f ANCA associated Vasculitis
Technical Summary
Experimental medicine study to investigate the combination of belimumab and rituximab in man.
Organisations
Publications
McClure M
(2018)
B cell therapy in ANCA-associated vasculitis: current and emerging treatment options.
in Nature reviews. Rheumatology
McClure ME
(2021)
Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models.
in Rheumatology (Oxford, England)